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upuytren’s disease (DD) is a benign fibroproliferative disorder of the 
hand, which causes the formation of nodules and cords in the palm and 
fingers. It may eventually lead to the inability to fully extend the 
fingers, giving rise to functional problems, such as difficulties shaking hands, 
putting hands in the pocket and grabbing objects. Reports about prevalence 
vary widely, but in the Netherlands it is around 22% in people over 50 years of 
age. [1] The disease is more common in people of European ancestry, in older 
persons and in males. [2, 3]  
 
Dupuytren’s disease is associated with Peyronie’s disease (PD), a fibrotic 
disorder of the penis. It causes deformities and pain in erection, ultimately 
impeding sexual intercourse. It is seen in up to 9% of men, although an 
underestimation due to shame is possible. [4] Both diseases seem to have a 
common histopathological phenotype, and show a concomitance of 20-40%. 
[5-7] Another disease that is associated with DD is Ledderhose disease, in 
which the plantar fascias are affected. This disease will not be subject of this 
thesis. 
 
Descriptions of DD date back to the seventeenth century, but it was Baron 
Guillaume Dupuytren, a French surgeon, whose name became associated with 
the disease because of a lecture he gave in Paris in 1831. [8, 9] PD is named 
after François Gigot de la Peyronie, also a French surgeon, and first-surgeon to 
King Louis XV. He described the induration of the penis in 1743. Dupuytren 
performed open fasciotomies in patients with DD, dividing the cords that had 
formed in the palmar aponeurosis, together with overlying skin, and reached 
satisfying results. Today, the golden standard in treating the disease is still 
open surgery, in which the cords and nodules are being removed (limited 
fasciectomy), sometimes even with the overlying skin (dermofasciectomy). 
The use of less invasive methods, such as percutaneous needle fasciotomy and 
injections with collagenase Clostridium histolyticum (Xiapex) in the cords, is 
becoming more popular. [10, 11] The downside of these newer techniques is 
that recurrences are more frequent following treatment, [10] which is 
understandable from a biological point of view: the affected tissues are left in 
place, and so, proliferation and contraction may continue. 
 
Treatment in PD is mostly conservative, that means counseling and sometimes 
using traction or vacuum devices to reduce penile deformity. Like in DD, 
injections with collagenase have shown efficacy and are the only FDA and EMA 
approved drug in treating PD. However, the manufacturer of Xiapex has 





Injections with steroids, and oral and topical medications haven’t proven 
effective. [12] Surgical therapy is only used in patients with deformity 
(curvature of more than 30 degrees) and stable, non-painful disease. [13] 
Penile shortening (plication, Nesbit procedure) and penile lengthening 
(grafting) techniques both have their pros and cons when it comes to results 
and complications. 
 
Still, for both types of fibromatosis, there is no definitive cure, and therapies 
are still focused on the symptoms of this disease. An important question to 
raise is if in the near future, DD and PD can be treated causally, that means, 
preventing the progression of early disease to the stage where functional 
problems occur, by focusing on the genetic and environmental factors that 
contribute to it. From a biological point of view, most research is focusing on 
pathways that enhance fibrosis in general and in both the palmar fascia and 
tunica albuginea in particular. Some of these studies have inspiring results. 
 
Both DD and PD (as well as Ledderhose disease) are examples of fibromatoses, 
i.e. soft tissue tumors caused by cell proliferation with a locally infiltrative 
growth pattern and – after removal - frequent local recurrence. However, 
malignant features such as metastatizing are absent and survival is not 
affected directly. The underlying mechanism of fibromatosis is cell 
proliferation and extracellular matrix deposition that exists from a plethora of 
contributing factors and pathways. Generally speaking, fibrosis is an end stage 
disease following inflammation, that is looked upon as ‘normal’ in wound 
healing, but also occurs in many diseases. In its inflammatory phase, multiple 
cells and cytokines are involved, each having their own specific function in this 
complex process. The constitution and interplay of these contributors have 
been studied extensively, and some of them are very relevant for the research 
that is the subject of this thesis, and will be mentioned later. Ultimately, the 
endpoint of the tissue response is the deposition of collagen, which, in normal 
conditions, is to a larger extent reversible. In DD and PD on one hand and in 
fibrotic diseases on the other however, once the inflammatory processes have 
led to fibrosis, the accumulation of surplus extracellular matrix becomes 
excessive and the process irreversible. This eventually leads to scarring, which 
in the case of affecting vital organs may lead to organ failure and possibly, even 
death. [14] In DD and PD it leads to the formation of nodules and cords, which 
cause functional problems. 
 
Pathophysiologically, key features of fibrosis are matrix deposition and 
contraction; both features are caused by uncontrolled myofibroblast activity. 
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The myofibroblast is found in wound healing tissue and shares characteristics 
from both fibroblasts (secretion of extracellular matrix and prominent 
endoplasmatic reticulum) and smooth muscle cells (contraction forces and 
presence of microfilament bundles). [15] Whereas the fibroblast is 
omnipresent in healthy tissue, myofibroblasts are almost absent under normal 
circumstances, but present in both normal and dysregulated wound healing, 
and fibrotic disorders. They are recognized as α-smooth muscle actin (α-SMA) 
positive cells. [16] Normally, the development of myofibroblasts depends on a 
number of different environmental cues, including tension in the matrix and 
exposure to a variety of different mediators. [16] Myofibroblasts have been 
identified as the key cell type in forming and occupying the early stage nodules 
in Dupuytren’s disease, with cords being less cellular and more tendon-like. 
[17, 18]  
 
Hallmarks of the fibromatoses are excessive collagen deposition in and around 
normal fascial structures in the palm of the hand in DD, and in the tunica 
albuginea in PD. According to Luck, DD develops in three progressive stages. 
[19] First, there is proliferation with high cellularity and random 
arrangements. This is followed by an involutional stage in which lines of 
tension appear along which the cells start to align. Lastly, the tissues end up in 
a residual stage with relatively acelullar structures surrounded by 
extracellular matrix. The distribution in certain types of collagen is dynamic in 
scars and DD. Collagen type III is mainly found in immature scar tissue and is 
known to have thinner fibrils than collagen type I. In progression of DD, there 
is a gradual decrease of collagen type III in relation to collagen type I. Also, the 
collagen type III is mainly found at the periphery of DD’s tissues, while type I 
makes up the majority of central portions. [20] As mentioned before, 
inflammation is an essential factor in the induction of fibrosis. A variety of pro-
inflammatory cytokines are known, too many to discuss in this thesis. 
However, we know that tumor necrosis factor (TNF) and transforming growth 
factor beta (TGF-β) both have a strong pro-fibrotic effect, as they are 
important regulators of the myofibroblast phenotype (e.g. differentiation and 
proliferation). [14] Elevated levels of TGF-β are seen in nodules and cords 
from patients with DD. [16, 21, 22] 
 
The involvement of Wnt signaling in fibrosis as induced by TGF-β is clear, and 
there is reciprocity between the Wnt and TGF-β signaling pathways. [23, 24] 
Moreover, TGF-β is involved in the Hippo signaling cascade, by activating Yes-
associated protein 1 (YAP1). [25] The expression of YAP1 is increased in 




decreased contraction force of the myofibroblasts. [26] The cross talk between 
these different pathways eventually leads to fibrosis, and in our case, to DD 
and PD. However, we still do not know how to interfere in these pathways to 
reduce fibrosis or cure the disease. 
 
The focus of this thesis is mainly on Wnt signaling, one of the many pathways 
involved in developmental processes. There are multiple Wnt genes and 
proteins that have specific, but similar functions, in the signaling pathway. [27] 
Wnt signaling has our special interest, as a result of the remarkable findings of 
our research group in 2010. This first of its kind genome-wide association 
study in DD probants revealed several loci in the human genome in DD for the 
first time, the majority of them being associated with the Wnt signaling 
pathway. [28] A subsequent study of our British colleagues and co-workers 
once more confirmed the relevance of Wnt signaling in Dupuytren’s disease. 
[29] The previously found susceptibility loci containing Wnt related genes 
were reconfirmed and others found. We started studying the functional impact 
of the expression of these Wnt genes found in our 2011 GWAS study and 
expanded it to the whole Wnt signaling pathway as well as its contributing 
genes in the following chapters. Variations in the Wnt pathway might 
predispose to Dupuytren’s disease, and maybe, fibrosis in general.  
 
The canonical pathway of Wnt signaling is the most extensively studied and 
has been shown to promote cell proliferation and survival via β-catenin. [30, 
31] Alternatively, Wnt proteins may signal via the non-canonical Wnt pathway, 
defined as all Wnt signaling activities that are apparently independent of β-
catenin. [32] During the research period that led to this thesis, it has become 
evident that canonical and non-canonical Wnt ligands and pathways are more 
diverse and also context-dependent. [27, 33] Therefore, this nomenclature has 
now become obsolete, but has been used in our already published papers and 
chapters. As far as possible, we will use the more correct terms β-catenin 
dependent and independent signaling. It is suggested that some environmental 
and genetic factors play an identical role in the development of Dupuytren’s 
and Peyronie’s diseases, such as Wnt signaling. [34] If this common pathway, 
or maybe different ones too, turn out to be equally important in both diseases, 







Aims of this thesis 
 
The main objective of this thesis was to elucidate some of the biological 
backgrounds of Dupuytren’s disease and Peyronie’s disease. Main research 
questions were the following: 
1. Are the Wnt genes as described by our research group in 2011 indeed 
dysregulated in Dupuytren’s cords and nodules? 
2. Is there a general alteration in Wnt signaling in Dupuytren’s tissues 
and does this connect to the fibrosis as seen in Dupuytren’s disease? 
3. What are the molecular differences between cords and nodules in 
Dupuytren’s disease? 
4. Will inhibiting the Wnt signaling pathway result in a less fibrotic 
phenotype in Dupuytren’s disease? 
5. Do we find a similar dysregulation in genes and pathways in plaques 
from Peyronie’s disease patients? 
 
Outline of this thesis 
 
Chapter 2 focuses on the results of a study on the expression of the Wnt-
related genes and proteins, in affected and non-affected tissues from 
Dupuytren’s patients, to answer our first research objective.  
 
Chapter 3 presents the results on the correlation of Wnt signaling and fibrosis 
and in Dupuytren’s disease and shows how intervening in the Wnt signaling 
pathway may change the fibrotic properties in diseased cells.  
 
Since both cords and nodules are a characteristic of Dupuytren’s disease, we 
investigated the differences between these two types of tissue on a molecular 
level. The results are described in Chapter 4.  
Knowing that the Wnt signaling pathway is involved in Dupuytren’s disease, 
we tried to block the production of Wnt proteins with a low-molecular weight 
Wnt-inhibiting molecule in normal dermal and affected Dupuytren’s 
fibroblasts. The outcomes of these experiments are presented in Chapter 5. 
 
Peyronie’s disease shares a common etiology with Dupuytren’s disease and 
about 20% of Peyronie’s patients show the typical cords and/or nodules of 
Dupuytren. Not much is known about the pathophysiology of Peyronie’s 




plaques from patients with Peyronie’s disease, and we focus on the 
dysregulations in collagens and collagen-modifying genes.  
 
Finally, Chapter 7 offers a general discussion on the above-mentioned studies 
and provides future perspectives regarding the pathophysiology of 
Dupuytren’s and Peyronie’s disease. Suggestions are given concerning new 
therapeutic targets, since a curative treatment does not yet exist for either one 
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